Presentación    
NEPHROLOGY
Composition
Name
Composition
Institution
Rafael Selgas Gutiérrez
Jefe de Servicio de Nefrología
Profesor Asociado. Facultad de Medicina
Hospital Universitario La Paz
Universidad Autónoma de Madrid
María Auxiliadora Bajo Rubio
Jefe de Sección de Nefrología
Profesora Asociado. Facultad de Medicina
Hospital Universitario La Paz
Universidad Autónoma de Madrid
María José Castro Notario
Enfermera
Hospital Universitario La Paz
Olga Costero Fernández
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Gloria del Peso Gilsanz
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
María José Fernández Reyes
Facultativo Especialista de Área en Nefrología
Hospital de Segovia
Helena García LLana
Psicóloga Investigadora
Hospital Universitario La Paz
María Elena González García
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Guadalupe González Mateo
Investigadora Postdoctoral
Hospital Universitario La Paz
Carlos Jiménez Martín
Jefe de Sección de Nefrología
Hospital Universitario La Paz
María Ovidia López Oliva
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Virginia Martínez Cabeza
Licenciada en Bioquímica
Hospital Universitario La Paz
Teresa Olea Tejero
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Ramón Peces Serrano
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Begoña Rivas Becerra
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
María Dolores Sánchez Niño
Investigadora Postdoctoral (Contrato Sara Borrell)
Hospital Universitario La Paz
Rafael Jesús Sánchez Villanueva
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Maximino Alberto Torre Carballada
Facultativo Especialista de Área en Nefrología
Hospital Universitario La Paz
Strategic Objective
The strategic objective of this care-research group is toenable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas. The lines of research are at times cross-sectional to the four components indicated for nephrology.
Research Lines
The lines of research are occasionally cross-sectional to the four components indicated for nephrology as a whole.
A) Incipient nephropathies and kidney disease progression:
• Glomerular and tubular nephropathies. New diagnostic markers and interventions.
• Organisational Research (computerisation, organisation of generational change in the department and network).
• Morbidity, mortality and progression of Diabetic Nephropathy and other glomerular nephropathies.
• Autosomal Dominant Polycystic Kidney Disease. Family Studies and treatment approaches.
• Association of cardiovascular disease with the progress of nephropathies (NEFRONA multicenter study, REDinREN).
• Incorporation of a psychologist into the department of nephrology: criteria and process. Issues on monitoring therapeutic adherence.
• Occult Hepatits C virus in different kidney disease situations.
 
B) Complications of dialysis
• Establishment of normal peritoneal functional in humans. Implications for patient survival and long-term treatment. New dialysis fluids. Aquaporin 1 (AQP1) and its genetic polymorphisms: relationship with peritoneal transport of water. Multicentre European study.
• The alternatively activated macrophage in peritoneal effluent (AAM): its relationship with defence and peritoneal fibrosis. CCL18 as a chemokine of AAM and a mediator of peritoneal fibrosis.
• Peritoneal biopsy for the complete evaluation of the peritoneal membrane. A correspondence study with cell and components findings in peritoneal effluent during kidney transplantation (Multicenter).
• Cardiovascular risk in patients with advanced kidney disease and on dialysis. Endocrine aspects. The abdominal adipocyte and adipocytokines. FABP antagonists as blockers of the adipocyte-macrophage response. Non-thyroidal diseases, influence on CKD patients. FGF 21 role in uremic insulin resistance.
• Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).
• Allergic reactions to hemodialysis membranes: mechanisms and alternatives.
C) Complications of kidney transplantation:
• Toxicity due to immunosuppressants. Ultrasound contrast in the analysis of renal microvasculature in kidney transplantation and complications.
• The involvement of CMV in the renal graft response: anticipated diagnosis.
• Kidney graft response. Thymoglobulin administered to a cadaver donor: effects on the expression of HLA antigens by tubular cells (clinical trial).
• Post-transplant monitorization of anti-HLA antibodies. Local development.
• The transplantation career since the values of the patient: health outcome repercussion.